Table 6.

Comparative analysis of the response of treatment by imatinib between CML patients with normal and mutated PTCH1

			PTCH1 gene		X2	P	RR (CI 95%)
			Mutated 19	Normal 24
Imatinip failure	NO	N	14	23	4.33	0.03*	2.20 (1.2-3.8)*
		%	37.8%	62.2%
	YES	N	5	1
		%	83.3%	16.7%

^*RR (Relative risk), ^*CI (confidence interval).